AQR Capital Management LLC Has $9.96 Million Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

AQR Capital Management LLC increased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 3.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 477,011 shares of the biopharmaceutical company's stock after acquiring an additional 17,659 shares during the period. AQR Capital Management LLC owned about 0.40% of Catalyst Pharmaceuticals worth $9,955,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. JPMorgan Chase & Co. lifted its position in shares of Catalyst Pharmaceuticals by 9.1% in the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company's stock valued at $8,116,000 after acquiring an additional 33,888 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 1,495 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Catalyst Pharmaceuticals by 13.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company's stock valued at $8,710,000 after buying an additional 50,888 shares in the last quarter. Redhawk Wealth Advisors Inc. acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter worth about $1,273,000. Finally, Spire Wealth Management lifted its position in shares of Catalyst Pharmaceuticals by 1,342.9% in the fourth quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company's stock worth $301,000 after buying an additional 13,429 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Trading Down 0.2%

NASDAQ CPRX traded down $0.06 during trading on Monday, hitting $23.32. The company had a trading volume of 175,383 shares, compared to its average volume of 1,106,650. Catalyst Pharmaceuticals, Inc. has a one year low of $14.75 and a one year high of $26.16. The company has a market cap of $2.84 billion, a price-to-earnings ratio of 19.69, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70. The company's fifty day moving average is $22.99 and its 200-day moving average is $22.40.

Analysts Set New Price Targets

A number of research analysts have issued reports on CPRX shares. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Stephens reiterated an "overweight" rating and issued a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Finally, Robert W. Baird boosted their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $32.29.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Brian Elsbernd sold 62,975 shares of the business's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This trade represents a 25.04% decrease in their position. The disclosure for this sale can be found here. 10.40% of the stock is owned by corporate insiders.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.